Fluvastatin sodium | CAS#93957-55-2 | HMG-CoA reductase inhibitor

MedKoo Cat#: 540140 | Name: Fluvastatin sodium

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fluvastatin sodium is an HMG-CoA reductase inhibitor used to lower cholesterol and lipid levels. It may inhibit RhoA. It also prevents viral replication of hepatitis C, decreases platelet activation, scavenges hydroxyl radicals, induces cell cycle arrest and apoptosis in hepatocellular carcinoma cells, and improves left ventricular function and prevents fibrosis in cardiac distress models.

Chemical Structure

Fluvastatin sodium

CAS#93957-55-2 (sodium)

Theoretical Analysis

MedKoo Cat#: 540140

Name: Fluvastatin sodium

CAS#: 93957-55-2 (sodium)

Chemical Formula: C24H25FNNaO4

Exact Mass: 433.1665

Molecular Weight: 433.45

Elemental Analysis: C, 66.50; H, 5.81; F, 4.38; N, 3.23; Na, 5.30; O, 14.76

Price and Availability

Size	Price	Availability	Quantity
1g	USD 285.00	2 Weeks
5g	USD 750.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

93957-55-2 (sodium) 94061-81-1 (sodium) 93957-54-1 (free acid) 500103-16-2 (calcium) 1009811-63-5 (potassium)

Synonym

Canef; Fluindostatin; Lescol XL; Lipaxan; Vastin; XU-62-320; XU62320; XU 62 320;

IUPAC/Chemical Name

sodium (3S,5R,E)-7-(3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl)-3,5-dihydroxyhept-6-enoate

InChi Key

ZGGHKIMDNBDHJB-RPQBTBOMSA-M

InChi Code

InChI=1S/C24H26FNO4.Na/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30;/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30);/q;+1/p-1/b12-11+;/t18-,19-;/m0./s1

SMILES Code

O=C([O-])C[C@@H](O)C[C@@H](O)/C=C/C(N1C(C)C)=C(C2=CC=C(F)C=C2)C3=C1C=CC=C3.[Na+]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Fluvastatin sodium (XU 62320) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM.

In vitro activity:

Fluvastatin significantly restored H2O2-induced neuronal death in a dose-dependent manner (P < 0.05) and reversed H2O2-induced oxidative stress and damage via restoring mitochondrial function in neuronal cells (P < 0.05). Reference: J Pharm Pharmacol. 2021 Mar 8;73(4):515-521. https://pubmed.ncbi.nlm.nih.gov/33793833/

In vivo activity:

Fluvastatin preconditioning in rats improved left ventricular dysfunction, reduced HMGB1/TLR4/NF-κB expressions, and inhibited cardiomyocyte apoptosis, autophagy, and inflammation reaction. Moreover, treatment with fluvastatin ameliorated myocardial injury by reducing infarct size, causing less damage to cardiac structure, downregulating autophagy-related protein expression and releasing pro-inflammation mediators. Reference: Mol Biol Rep. 2021 May;48(5):3893-3901. https://pubmed.ncbi.nlm.nih.gov/34032975/

	Solvent	mg/mL	mM
Solubility
	DMSO	65.2	150.35
	Water	14.4	33.27

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 433.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Wang M, Wang J, Liu M, Chen G. Fluvastatin protects neuronal cells from hydrogen peroxide-induced toxicity with decreasing oxidative damage and increasing PI3K/Akt/mTOR signalling. J Pharm Pharmacol. 2021 Mar 8;73(4):515-521. doi: 10.1093/jpp/rgaa058. PMID: 33793833. 2. Zhao K, Tian Y, Wang J, Chen C, Pan B, Yan Z, Zhu S, Xu K. Fluvastatin-Pretreated Donor Cells Attenuated Murine aGVHD by Balancing Effector T Cell Distribution and Function under the Regulation of KLF2. Biomed Res Int. 2020 Dec 19;2020:7619849. doi: 10.1155/2020/7619849. PMID: 33415155; PMCID: PMC7769635. 3. Ding HS, Yang J, Yang J, Guo X, Tang YH, Huang Y, Chen Z, Fan ZX, Huang CX. Fluvastatin attenuated ischemia/reperfusion-induced autophagy and apoptosis in cardiomyocytes through down-regulation HMGB1/TLR4 signaling pathway. Mol Biol Rep. 2021 May;48(5):3893-3901. doi: 10.1007/s11033-021-06326-9. Epub 2021 May 25. PMID: 34032975. 4. Yu JS, Shin DH, Kim JS. Repurposing of Fluvastatin as an Anticancer Agent against Breast Cancer Stem Cells via Encapsulation in a Hyaluronan-Conjugated Liposome. Pharmaceutics. 2020 Nov 24;12(12):1133. doi: 10.3390/pharmaceutics12121133. PMID: 33255298; PMCID: PMC7760927.

In vitro protocol:

In vivo protocol:

1. Ding HS, Yang J, Yang J, Guo X, Tang YH, Huang Y, Chen Z, Fan ZX, Huang CX. Fluvastatin attenuated ischemia/reperfusion-induced autophagy and apoptosis in cardiomyocytes through down-regulation HMGB1/TLR4 signaling pathway. Mol Biol Rep. 2021 May;48(5):3893-3901. doi: 10.1007/s11033-021-06326-9. Epub 2021 May 25. PMID: 34032975. 2. Yu JS, Shin DH, Kim JS. Repurposing of Fluvastatin as an Anticancer Agent against Breast Cancer Stem Cells via Encapsulation in a Hyaluronan-Conjugated Liposome. Pharmaceutics. 2020 Nov 24;12(12):1133. doi: 10.3390/pharmaceutics12121133. PMID: 33255298; PMCID: PMC7760927.

1: Borgmann SH, Bernardi LS, Rauber GS, Oliveira PR, Campos CE, Monti G, Cuffini SL, Cardoso SG. Solid-state characterization and dissolution properties of Fluvastatin sodium salt hydrates. Pharm Dev Technol. 2013 Mar-Apr;18(2):525-34. doi: 10.3109/10837450.2012.727000. Epub 2012 Oct 4. PubMed PMID: 23033850. 2: Yildiz A, Gul CB, Ocak N, Ersoy A, Sag S, Oruc A, Ayar Y, Dagel T, Dirican M, Gullulu M. Fluvastatin Decreases Oxidative Stress in Kidney Transplant Patients. Transplant Proc. 2015 Dec;47(10):2870-4. doi: 10.1016/j.transproceed.2015.10.027. PubMed PMID: 26707305. 3: Sekiya A, Morishita E, Maruyama K, Torishima H, Ohtake S. Fluvastatin Upregulates the Expression of Tissue Factor Pathway Inhibitor in Human Umbilical Vein Endothelial Cells. J Atheroscler Thromb. 2015 Jul 23;22(7):660-8. doi: 10.5551/jat.28175. Epub 2015 Jan 16. PubMed PMID: 25735397. 4: Zhao S, Wang F, Yang K, Hao Y, Li G, Yang M, Yang Z. [Efficacy and safety of fluvastatin extended-release tablets in Chinese patients with hyperlipidemia: a multi-center, randomized, double-blind, double dummy, active-controlled, parallel-group study]. Zhonghua Nei Ke Za Zhi. 2014 Jun;53(6):455-9. Chinese. PubMed PMID: 25146513. 5: Sławińska-Brych A, Zdzisińska B, Kandefer-Szerszeń M. Fluvastatin inhibits growth and alters the malignant phenotype of the C6 glioma cell line. Pharmacol Rep. 2014 Feb;66(1):121-9. doi: 10.1016/j.pharep.2014.01.002. Epub 2014 Feb 1. PubMed PMID: 24905317. 6: Kolawole EM, McLeod JJ, Ndaw V, Abebayehu D, Barnstein BO, Faber T, Spence AJ, Taruselli M, Paranjape A, Haque TT, Qayum AA, Kazmi QA, Wijesinghe DS, Sturgill JL, Chalfant CE, Straus DB, Oskeritzian CA, Ryan JJ. Fluvastatin Suppresses Mast Cell and Basophil IgE Responses: Genotype-Dependent Effects. J Immunol. 2016 Feb 15;196(4):1461-70. doi: 10.4049/jimmunol.1501932. Epub 2016 Jan 15. PubMed PMID: 26773154; PubMed Central PMCID: PMC4744515. 7: Galus R, Włodarski K, Malejczyk J, Jóźwiak J. Fluvastatin influences hair color in C57BL/6 mice. Int J Mol Sci. 2013 Jul 10;14(7):14333-45. doi: 10.3390/ijms140714333. PubMed PMID: 23846727; PubMed Central PMCID: PMC3742247. 8: Korhonova M, Doricakova A, Dvorak Z. Optical Isomers of Atorvastatin, Rosuvastatin and Fluvastatin Enantiospecifically Activate Pregnane X Receptor PXR and Induce CYP2A6, CYP2B6 and CYP3A4 in Human Hepatocytes. PLoS One. 2015 Sep 14;10(9):e0137720. doi: 10.1371/journal.pone.0137720. eCollection 2015. PubMed PMID: 26366873; PubMed Central PMCID: PMC4569258. 9: Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A, Fukuda T, Matsushita Y, Narahara Y, Osada Y, Yamaguchi H, Nakatsuka K, Iwakiri K, Kawamoto C, Sakamoto C. Effect of fluvastatin on 24-week telaprevir-based combination therapy for hepatitis C virus genotype 1b-infected chronic hepatitis C. Eur J Gastroenterol Hepatol. 2014 Jul;26(7):781-7. doi: 10.1097/MEG.0000000000000105. PubMed PMID: 24732752. 10: Kubatka P, Stollárová N, Škarda J, Žihlavníková K, Kajo K, Kapinová A, Adamicová K, Péč M, Dobrota D, Bojková B, Kassayová M, Orendáš P. Preventive effects of fluvastatin in rat mammary carcinogenesis. Eur J Cancer Prev. 2013 Jul;22(4):352-7. doi: 10.1097/CEJ.0b013e32835b385d. PubMed PMID: 23212095. 11: Peng J, Zhang D, Ma Y, Wang G, Guo Z, Lu J. Protective effect of fluvastatin on influenza virus infection. Mol Med Rep. 2014 Jun;9(6):2221-6. doi: 10.3892/mmr.2014.2076. Epub 2014 Mar 27. PubMed PMID: 24676773. 12: Habara M, Nasu K, Terashima M, Ko E, Yokota D, Ito T, Kurita T, Teramoto T, Kimura M, Kinoshita Y, Tsuchikane E, Asakura Y, Matsubara T, Suzuki T. Impact on optical coherence tomographic coronary findings of fluvastatin alone versus fluvastatin + ezetimibe. Am J Cardiol. 2014 Feb 15;113(4):580-7. doi: 10.1016/j.amjcard.2013.10.038. Epub 2013 Nov 22. PubMed PMID: 24388622. 13: Goard CA, Chan-Seng-Yue M, Mullen PJ, Quiroga AD, Wasylishen AR, Clendening JW, Sendorek DH, Haider S, Lehner R, Boutros PC, Penn LZ. Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells. Breast Cancer Res Treat. 2014 Jan;143(2):301-12. doi: 10.1007/s10549-013-2800-y. Epub 2013 Dec 17. PubMed PMID: 24337703. 14: Vincze J, Jenes Á, Füzi M, Almássy J, Németh R, Szigeti G, Dienes B, Gaál Z, Szentesi P, Jóna I, Kertai P, Paragh G, Csernoch L. Effects of fluvastatin and coenzyme Q10 on skeletal muscle in normo- and hypercholesterolaemic rats. J Muscle Res Cell Motil. 2015 Jun;36(3):263-74. doi: 10.1007/s10974-015-9413-5. Epub 2015 Apr 29. PubMed PMID: 25920381. 15: Zhang L, Liu J, Liu Y, Xu Y, Zhao X, Qian J, Sun B, Xing C. Fluvastatin inhibits the expression of fibronectin in human peritoneal mesothelial cells induced by high-glucose peritoneal dialysis solution via SGK1 pathway. Clin Exp Nephrol. 2015 Jun;19(3):336-42. doi: 10.1007/s10157-014-0991-0. Epub 2014 Jun 20. PubMed PMID: 24942605. 16: Sheridan DA, Bridge SH, Crossey MM, Felmlee DJ, Fenwick FI, Thomas HC, Neely RD, Taylor-Robinson SD, Bassendine MF. Omega-3 fatty acids and/or fluvastatin in hepatitis C prior non-responders to combination antiviral therapy - a pilot randomised clinical trial. Liver Int. 2014 May;34(5):737-47. doi: 10.1111/liv.12316. Epub 2013 Oct 14. PubMed PMID: 24118830. 17: Sevin G, Yasa M, Akcay DY, Kirkali G, Kerry Z. Different responses of fluvastatin to cholesterol-induced oxidative modifications in rabbits: evidence for preventive effect against DNA damage. Cell Biochem Funct. 2013 Jun;31(4):325-32. doi: 10.1002/cbf.2903. Epub 2012 Oct 11. PubMed PMID: 23055364. 18: Xu HR, Chen WL, Chu NN, Li XN, Zhu JR. The difference in pharmacokinetics and pharmacodynamics between extended-release fluvastatin and immediate-release fluvastatin in healthy Chinese subjects. J Biomed Biotechnol. 2012;2012:386230. doi: 10.1155/2012/386230. Epub 2012 Jul 1. PubMed PMID: 22811596; PubMed Central PMCID: PMC3395249. 19: Chang JH, Lee KJ, Kim SK, Yoo DH, Kang TY. Validity of SW982 synovial cell line for studying the drugs against rheumatoid arthritis in fluvastatin-induced apoptosis signaling model. Indian J Med Res. 2014 Jan;139(1):117-24. PubMed PMID: 24604047; PubMed Central PMCID: PMC3994728. 20: Larocque G, Arnold AA, Chartrand E, Mouget Y, Marcotte I. Effect of sodium bicarbonate as a pharmaceutical formulation excipient on the interaction of fluvastatin with membrane phospholipids. Eur Biophys J. 2010 Nov;39(12):1637-47. doi: 10.1007/s00249-010-0622-y. Epub 2010 Aug 27. PubMed PMID: 20798935.